Hormonal
Initiating anti-obesity medications (AOMs) more than 12 months after bariatric surgery is associated with a significantly lower risk of adverse events compared to initiating them within the first 12 months.
If you are considering weight loss medication after bariatric surgery, current evidence suggests that waiting until at least 12 months post-surgery to start the medication is associated with a significantly lower risk of adverse events compared to starting within the first year. This may allow for better surgical recovery before adding pharmacological stress.
AOM initiation ≥12 months after surgery was associated with lower risk of AEs compared to <12 months (aOR 0.01 [95% CI 0.0–0.01]; p < 0.001).
Why this rating
Retrospective cohort study; strong statistical association but potential confounding by indication.
Source
Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery
Jason M. Samuels et al. · Diabetes Obesity and Metabolism · 2024
DOI 10.1111/dom.15737
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →